BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $510,056 | -18.2% | 13,515 | -1.2% | 0.05% | -24.2% |
| Q2 2023 | $623,489 | +12.3% | 13,685 | 0.0% | 0.06% | +19.2% |
| Q1 2023 | $555,064 | -20.4% | 13,685 | 0.0% | 0.05% | -18.8% |
| Q4 2022 | $697,524 | -9.4% | 13,685 | -4.3% | 0.06% | -11.1% |
| Q3 2022 | $770,000 | -25.6% | 14,293 | -11.3% | 0.07% | -12.2% |
| Q2 2022 | $1,035,000 | -16.7% | 16,115 | +0.6% | 0.08% | -10.9% |
| Q1 2022 | $1,242,000 | -9.7% | 16,018 | 0.0% | 0.09% | +9.5% |
| Q4 2021 | $1,375,000 | +6.8% | 16,018 | 0.0% | 0.08% | -9.7% |
| Q3 2021 | $1,288,000 | -0.7% | 16,018 | -0.6% | 0.09% | -12.3% |
| Q2 2021 | $1,297,000 | -9.7% | 16,118 | -5.4% | 0.11% | -20.9% |
| Q1 2021 | $1,437,000 | +3.9% | 17,040 | -1.2% | 0.13% | -12.4% |
| Q4 2020 | $1,383,000 | +37.5% | 17,240 | +37.8% | 0.15% | +13.3% |
| Q3 2020 | $1,006,000 | +61.5% | 12,510 | +73.0% | 0.14% | +25.0% |
| Q2 2020 | $623,000 | -23.2% | 7,230 | -27.7% | 0.11% | -43.5% |
| Q1 2020 | $811,000 | -55.8% | 9,995 | -54.4% | 0.19% | -35.3% |
| Q4 2019 | $1,833,000 | -4.4% | 21,925 | 0.0% | 0.30% | -9.8% |
| Q3 2019 | $1,918,000 | +73.7% | 21,925 | +62.6% | 0.33% | +40.9% |
| Q2 2019 | $1,104,000 | -41.6% | 13,485 | -42.0% | 0.23% | -18.3% |
| Q1 2019 | $1,891,000 | +15.4% | 23,255 | -6.6% | 0.28% | +13.1% |
| Q4 2018 | $1,639,000 | – | 24,900 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |